The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the ...

Nucleic acid therapeutics are based on nucleic acids or closely related chemical compounds. They include antisense oligonucleotides, aptamers and small interfering RNAs, and are typically ...

At first, researchers thought that antisense drugs would prove so specific there would be few side effects. But toxicity-related problems did arise in initial animal studies of antisense drugs in the ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the ... This webinar will explore the most recent ASO chemical modification: locked nucleic acid (LNA), which confers high ...

(OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs ...

The upcoming Therapeutic Oligonucleotides 2025 conference, hosted by ELRIG, will take place at AstraZeneca’s R&D site in ...

Splice-switching antisense oligonucleotide controlling tumor suppressor REST is a novel therapeutic medicine for neuroendocrine cancer, Molecular Therapy - Nucleic Acids (2024). DOI: 10.1016/j.omtn.

General and administrative expense for the year ended December 31, 2024 increased to $4.7 million, compared to $4.2 million for the year ended December 31, 2023 primarily due to increased salaries and ...

Updated results from BP1001-A obesity and Type 2 diabetes testing from the second stage of pre-clinical testing are as follows: Previously, Bio-Path reported BP1001-A increased insulin sensitivity in ...